JP2010510323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510323A5 JP2010510323A5 JP2009538506A JP2009538506A JP2010510323A5 JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5 JP 2009538506 A JP2009538506 A JP 2009538506A JP 2009538506 A JP2009538506 A JP 2009538506A JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037976 chronic inflammation Diseases 0.000 claims description 18
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 18
- 230000003432 anti-folate effect Effects 0.000 claims description 11
- 229940127074 antifolate Drugs 0.000 claims description 11
- 239000004052 folic acid antagonist Substances 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 8
- 229960000485 methotrexate Drugs 0.000 claims description 8
- 208000004235 neutropenia Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 230000003278 mimic effect Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 101710205889 Cytochrome b562 Proteins 0.000 claims description 3
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims description 3
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims description 3
- 102000019298 Lipocalin Human genes 0.000 claims description 3
- 108050006654 Lipocalin Proteins 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical compound COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 238000000034 method Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86078006P | 2006-11-21 | 2006-11-21 | |
| US60/860,780 | 2006-11-21 | ||
| US90274207P | 2007-02-21 | 2007-02-21 | |
| US60/902,742 | 2007-02-21 | ||
| PCT/US2007/085402 WO2008064321A2 (en) | 2006-11-21 | 2007-11-21 | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510323A JP2010510323A (ja) | 2010-04-02 |
| JP2010510323A5 true JP2010510323A5 (enExample) | 2011-01-13 |
| JP5410293B2 JP5410293B2 (ja) | 2014-02-05 |
Family
ID=39386167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538506A Expired - Fee Related JP5410293B2 (ja) | 2006-11-21 | 2007-11-21 | Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080206241A1 (enExample) |
| EP (2) | EP2101780B1 (enExample) |
| JP (1) | JP5410293B2 (enExample) |
| KR (1) | KR101517251B1 (enExample) |
| CN (2) | CN101605547A (enExample) |
| AU (1) | AU2007323541B2 (enExample) |
| BR (1) | BRPI0719109A2 (enExample) |
| CA (1) | CA2670288C (enExample) |
| EA (1) | EA200900709A1 (enExample) |
| ES (1) | ES2432173T3 (enExample) |
| IL (1) | IL198829A0 (enExample) |
| MX (1) | MX2009005398A (enExample) |
| NZ (1) | NZ598345A (enExample) |
| SG (1) | SG176503A1 (enExample) |
| WO (1) | WO2008064321A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2101780B1 (en) | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| JP5781762B2 (ja) * | 2007-08-10 | 2015-09-24 | プロテリックス、インク | ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| DK2215119T3 (da) | 2007-11-13 | 2013-02-04 | Evec Inc | Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. |
| WO2009091905A1 (en) * | 2008-01-15 | 2009-07-23 | Kalobios Pharmaceuticals, Inc. | Methods of treating bone-loss disorders using a gm-csf antagonist |
| JP5608635B2 (ja) * | 2008-04-07 | 2014-10-15 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 心不全処置のためのｇｍ−ｃｓｆの中和方法 |
| ES2704835T3 (es) | 2008-04-28 | 2019-03-20 | Humanigen Inc | Anticuerpos contra el factor estimulante de colonias de granulocitos y macrófagos |
| CA2746827C (en) | 2008-12-22 | 2018-01-23 | The University Of Melbourne | Osteoarthritis treatment |
| AU2015224416B2 (en) * | 2008-12-22 | 2017-04-20 | The University Of Melbourne | Osteoarthritis treatment |
| ES2685895T3 (es) * | 2008-12-22 | 2018-10-15 | The University Of Melbourne | Tratamiento del dolor |
| WO2010093814A1 (en) * | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
| CN102459340A (zh) * | 2009-04-23 | 2012-05-16 | 特罗科隆科学有限公司 | 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体 |
| KR20120011883A (ko) * | 2009-05-05 | 2012-02-08 | 모르포시스 아게 | 다발성 경화증의 치료 |
| JP2014520784A (ja) * | 2011-07-06 | 2014-08-25 | モルフォシス・アー・ゲー | 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| SG10201803778PA (en) * | 2012-09-20 | 2018-06-28 | Morphosys Ag | Treatment for rheumatoid arthritis |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| JP2016536327A (ja) * | 2013-08-30 | 2016-11-24 | タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ |
| JP6360696B2 (ja) * | 2014-03-18 | 2018-07-18 | 日本光電工業株式会社 | 血液検査装置および血液検査方法 |
| JP2017515828A (ja) * | 2014-05-19 | 2017-06-15 | メディミューン リミテッド | 関節リウマチのための治療 |
| WO2018031968A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| CA3036509C (en) | 2016-09-19 | 2022-10-25 | I-Mab | Anti-gm-csf antibodies and uses thereof |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10870703B2 (en) | 2017-10-02 | 2020-12-22 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| JP2022513412A (ja) * | 2018-10-31 | 2022-02-07 | ヒューマニゲン インコーポレイティッド | 癌を治療するための物質及び方法 |
| CN115605508A (zh) * | 2020-03-08 | 2023-01-13 | 赫曼尼根公司（Us） | 用于治疗冠状病毒感染和所产生的炎症诱导的肺损伤的方法 |
| EP4255483A4 (en) * | 2020-12-04 | 2025-07-09 | CSL Innovation Pty Ltd | METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| WO2022192093A1 (en) * | 2021-03-08 | 2022-09-15 | Humanigen, Inc. | Methods for treating coronavirus infection and resulting inflammation-induced lung injury |
| WO2023138499A1 (zh) * | 2022-01-20 | 2023-07-27 | 舒泰神（北京）生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| HUT63181A (en) * | 1989-07-14 | 1993-07-28 | Schering Corp | Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CZ292465B6 (cs) | 1996-02-09 | 2003-09-17 | Abbott Laboratories (Bermuda) Ltd. | Lidské protilátky k lidskému TNFalfa |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| WO2003068924A2 (en) | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Fusion proteins of humanized g250 specific antibodies and uses thereof |
| GB0224082D0 (en) * | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
| NZ541480A (en) * | 2003-03-12 | 2008-03-28 | Genentech Inc | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| JP4979378B2 (ja) * | 2003-07-23 | 2012-07-18 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連の使用のための化合物 |
| CA2553692C (en) | 2004-01-20 | 2014-10-07 | Kalobios, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| BRPI0513110A (pt) * | 2004-07-16 | 2008-04-29 | Kyorin Seiyaku Kk | medicamento compreendendo composto sulfeto diaril ou composto éter diaril tendo uma estrutura 2-amina-1, 3-propanediol tendo uma atividade de redução de linfócitos perifericamente circulante, em combinação com um agente imunosupressivo e/ou um agente antiinflamatório e método de expressão de prevenção do efeito secundário |
| CA2587158C (en) | 2004-11-16 | 2016-01-12 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| CA2608498C (en) | 2005-05-18 | 2017-04-04 | Morphosys Ag | Anti-gm-csf antibodies and uses therefor |
| WO2007082177A2 (en) * | 2006-01-06 | 2007-07-19 | Mount Sinai School Of Medicine Of New York University | Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity |
| HRP20170024T1 (hr) * | 2006-02-08 | 2017-03-10 | Morphotek, Inc. | Antigeni peptidi gm-csf i protutijela protiv gm-csf |
| CN103641915B (zh) | 2006-03-27 | 2017-04-12 | 医学免疫有限公司 | Gm‑csf受体结合元件 |
| DE102006033837A1 (de) * | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
| EP2101780B1 (en) | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
-
2007
- 2007-11-21 EP EP07868831.4A patent/EP2101780B1/en not_active Revoked
- 2007-11-21 MX MX2009005398A patent/MX2009005398A/es active IP Right Grant
- 2007-11-21 SG SG2011085834A patent/SG176503A1/en unknown
- 2007-11-21 CA CA2670288A patent/CA2670288C/en not_active Expired - Fee Related
- 2007-11-21 EP EP11182971A patent/EP2402013A1/en not_active Withdrawn
- 2007-11-21 US US11/944,162 patent/US20080206241A1/en not_active Abandoned
- 2007-11-21 CN CNA2007800495322A patent/CN101605547A/zh active Pending
- 2007-11-21 AU AU2007323541A patent/AU2007323541B2/en not_active Ceased
- 2007-11-21 EA EA200900709A patent/EA200900709A1/ru unknown
- 2007-11-21 WO PCT/US2007/085402 patent/WO2008064321A2/en not_active Ceased
- 2007-11-21 CN CN201510674256.5A patent/CN105435223A/zh active Pending
- 2007-11-21 BR BRPI0719109-0A2A patent/BRPI0719109A2/pt not_active IP Right Cessation
- 2007-11-21 ES ES07868831T patent/ES2432173T3/es active Active
- 2007-11-21 NZ NZ598345A patent/NZ598345A/xx not_active IP Right Cessation
- 2007-11-21 JP JP2009538506A patent/JP5410293B2/ja not_active Expired - Fee Related
- 2007-11-21 KR KR1020097012906A patent/KR101517251B1/ko not_active Expired - Fee Related
-
2009
- 2009-05-19 IL IL198829A patent/IL198829A0/en unknown
-
2015
- 2015-05-14 US US14/712,627 patent/US20150246121A1/en not_active Abandoned